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Liver Metastasectomy and Systemic
Therapy Improve Overall Survival
Compared With Surgery Alone After
Curative Liver Resection of Colorectal
Metastases in a Developing Country
(Costa Rica)
abstract
Background Resection of liver-isolated metastases of colorectal cancer (CRC) offers the greatest like-
lihood of cure. Nevertheless, recurrence rates after this procedure are high, and chemotherapy is a
reasonable choice with inconclusive evidence. We aimed to determine if there is a survival difference
between patients receiving systemic therapy with surgery versus surgery alone for resection of liver
metastases.
Methods From a source population of 170 patients treated in our National Centre (Centro Nacional de
Cirugı´a Hepatobiliar, San Jose´, Costa Rica), with liver metastases from various primary sites, we selected
51 patients with CRC who underwent hepatic resection with curative intent. We categorized patients
according to the treatment received (fluoropyrimidine-based chemotherapy plus or minus monoclonal
antibody and surgery v surgery alone) and then calculated the overall survival (OS) rate according to the
Kaplan-Meier method. A Cox proportional hazard model was used to assess the influence of potential
confounding variables on OS.
Results After a median follow-up of 41.6 months, OS was significantly better for patients treated with
systemic therapy (before and/or after hepatic resection) versus surgery alone (3-year OS: 66.7% v 41.7%;
hazard ratio, 0.37;95%CI,0.15 to0.91; log-rank test:P= .025). Therewerenodifferencesamongpatients
who underwent neoadjuvant (48.7%), perioperative (46.2%), and adjuvant therapy (5.1%). The use of
systemic therapy was significantly associated with better OS after adjustment for confounding variables
(hazard ratio, 0.23; 95% CI, 0.07 to 0.92; P = .03).
Conclusion Our findings support the use of systemic therapy (either perioperative, neoadjuvant, or ad-
juvant) as part of isolated hepatic metastasectomy from CRC.
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INTRODUCTION
Colorectal cancer (CRC) is the second and third
most common cancer in women and men, re-
spectively; it is a leading cause of cancer-related
mortality worldwide.1 Approximately 50% of pa-
tients develop hepatic metastases, and in one-
third of cases the liver is the only affected organ. At
the time of diagnosis, synchronous isolated liver
metastases are detected in approximately 25% of
patients. If these lesions become resectable, the
reported 5-year survival rate increases from 30%
to 65%, and fewer than 2% of patients are still
alive 5 years after diagnosis without any medical
or surgical treatment.2
For this reason, surgical resection of isolated liver
metastases is the treatment of choice when fea-
sible. Nevertheless, recurrence rates after this
procedure are high, making systemic treatment
plausible to achieve longer survival.3 Although
the use of perioperative and adjuvant therapy has
Paula Quesada-Soto
Denis Landaverde
Allan Ramos-Esquivel
Paula Quesada-Soto and
Denis Landaverde,
Hospital Me´xico; and Allan
Ramos-Esquivel, Hospital
San Juan de Dios, San
Jose´, Costa Rica.
Presented at the World
Congress on
Gastrointestinal Cancer,
Barcelona, Spain, July
1-4, 2015.
Authors’ disclosures of
potential conflicts of
interest and contributions
are found at the end of this
article.
Corresponding author:
Allan Ramos-Esquivel,
Ciudad Universitario
Rodrigo Facio, Escuela de
Medicina, Departamento
de Farmacologı´a, San
Jose´, Costa Rica, Apdo.
2082; e-mail: allan.
ramos@ucr.ac.cr.
31 Volume 3, Issue 1, February 2017 jgo.org JGO – Journal of Global Oncology
© 2016 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License
Downloaded from ascopubs.org by 12.219.81.130 on June 5, 2018 from 012.219.081.130
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
shown some efficacy in patients with resectable
liver metastases, the indication of systemic ther-
apy after curative surgery for liver metastases is
currently uncertain. There are contradictory re-
sults in the literature as the result of scarce data
and trials that closedprematurely becauseof slow
accrual. Hence, clear evidence for a survival ben-
efit of systemic treatment compared with obser-
vation alone has not been well established.4,5
Nevertheless, a recent meta-analysis of random-
ized and observational clinical trials showed a
clinical benefit in terms of overall survival (OS)
and recurrence-free survival for those patients
who underwent hepatic metastasectomy and re-
ceived systemic chemotherapy.6
Furthermore, there is a current debate about the
preference of neoadjuvant, perioperative, or ad-
juvant treatment in these patients, and the best
regimen remains to be determined.7,8 Moreover,
there are scarce data regarding this procedure in
developing countries, where access to medical
care is often limited.
In this retrospective study, we aimed to determine if
patients receiving any kind of systemic therapy plus
surgery obtain a better OS than patients treated with
surgery alone for CRC liver metastases.
METHODS
Between January 2009 and December 2014, we
reviewed the clinical records of 170 patients treated
in the National Centre of Hepatobiliary Surgery (San
Jose´, Costa Rica) who underwent hepatic meta-
stasectomy. We then selected 51 patients who
underwent curative hepatic resection of colorec-
talmetastases. The attending surgeonperformed
the surgical procedure (metastasectomy, seg-
mentectomy, or partial hepatectomy) after mul-
tidisciplinary planning. Patients were considered
candidates for this approach if they had no sig-
nificant medical condition that contraindicated
the surgical procedure, an Eastern Cooperative
Oncology Group performance status score < 2,
and no detectable extrahepatic tumor.
The follow-up consisted of clinical evaluation per-
formed at least every 6 weeks during the first year
and at least every 3 months thereafter. Evaluation
includedphysical examination, serumcarcinoem-
bryonic antigen levels, and at least three annual
thorax and abdomen computed tomography scans
or an abdominal ultrasound every 4 or 6 months.
Patients received conversion (ie, neoadjuvant),
perioperative, adjuvant, or no systemic therapy,
according to the recommendation of the multi-
disciplinary team. For the purpose of this work,
we considered conversion (neoadjuvant) chemo-
therapy solely as the administration of preoperative
treatment for resectable or borderline-resectable
liver metastases. The administration of chemo-
therapy before and after the surgical procedure
was considered perioperative treatment. Lastly,
adjuvant therapy refers to systemic treatment
received after surgical resection.
The tumor board decided upon the most suitable
chemotherapeutic regimen (fluoropyrimidine based)
with or without the addition of any monoclonal
antibody (bevacizumabor cetuximab). Individual
patient data were collected, including age, sex,
tumor stage and grade, as well as primary site,
number, and size of liver metastases.
All procedures performed in studies involving hu-
man participants were in accordance with the
ethical standardsof the institutional researchcom-
mittee andwith the 1964Helsinki Declaration and
its later amendments or comparable ethical stan-
dards. Because of the retrospective nature of this
study, formal consent was not required.
Categorical variables are presented as percent-
ages and were compared by the x2 test or Fisher’s
exact test when applicable. Continuous variables
are presented as the mean 6 standard deviation
and were analyzed by theMann-WhitneyU test as
appropriate. Follow-up time was calculated as the
time from surgery to death or to August 1, 2014.
Disease-free survival (DFS) and OS were calcu-
lated using the Kaplan-Meier method, measuring
time from thedate of surgery to thedate of failureat
any site (determined by RECIST 1.1) or to the date
of death from any cause, respectively. Using the
log-rank test, we compared patients who received
systemic treatment plus surgery with those who
underwent only the surgical procedure. The Cox
proportional hazards regression model was used
to calculate crude hazard ratios.
A P value , .05 was considered statistically sig-
nificant. Data were analyzed using SPSS for Mac
version 20.0 (SPSS, Chicago, IL).
RESULTS
Patients had a median follow-up of 41.6 months
(interquartile range: 29.2 to 44.4months). Patient
demographics and clinical variables stratified
according to treatment received are presented
in Table 1. Treatment modalities were as fol-
lows: neoadjuvant therapy (conversion therapy),
19 patients (48.7%); perioperative chemother-
apy, 18 patients (46.2%); and adjuvant therapy,
two patients (5.1%). The regimen used most fre-
quently was capecitabine plus oxaliplatin (XELOX)
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in 20 patients; followed by fluorouracil, leucov-
orin, and oxaliplatin (FOLFOX-6) plus bevacizu-
mab in nine patients. Other regimens were as
follows: FOLFOX-6 in three patients; fluoro-
uracil, leucovorin, and irinotecan (FOLFIRI) in
three patients; XELOX plus cetuximab in one
patient; and capecitabine alone in the remain-
ing patient.
The majority of surgical procedures consisted of
segmentectomy or tumorectomy (in 28 patients);
partial hepatectomywas performed in the remain-
ing cases. Seven patients also received radiofre-
quency ablation of suspected lesions. All of the
procedures were done with curative intent. Only
five patients (10%) presented with surgical com-
plications, including infection or bleeding.Noneof
these cases were fatal.
The median OS for all patients was 41.8 months
(95% CI, 39.25 to 44.36). As depicted in Figure 1,
patients who received systemic therapy had a me-
dian OS of 44.4 months (95% CI, 39.47 to 44.36)
compared with 36.3 months (95% CI, 21.12 to
51.48) for patients who underwent surgery alone
(P = .025). The 3-year OS rate was 41.7% in pa-
tients treated with surgery alone versus 66.7% in
those who also received systemic treatment. There
were no statistically significant differences among
any of the systemic treatment modalities (neoadju-
vant, perioperative, or adjuvant; P = .91).
During the follow-up period, 36 patients (70.6%)
had relapses, and 29 patients (83%) had re-
currences confined to the liver. Among these
patients, a second metastasectomy followed
by fluoropyrimidine-based chemotherapy was
Table 1 – Clinical Characteristics of the Studied Population According to Treatment Received
Variable Patients (n 5 51) Surgery Only (n 5 12) Systemic Treatment and Surgery (n 5 39) P
Male sex, No. (%) 39 (76.5) 7 (58.3) 32 (82.1) .09
Age, years (mean 6 SD) 61.72 6 14.5 63.83 6 19.7 61.07 6 12.8 .90
T (primary site), No.(%) .69
T1 3 (5.9) 1 (8.3) 2 (5.1)
T2 8 (15.7) 2 (16.7) 6 (15.4)
T3 33 (64.7) 7 (58.3) 26 (66.7)
T4 7 (13.7) 2 (16.7) 5 (12.8)
N (primary site), No. (%) .95
N0 3 (5.9) 1 (8.3) 2 (5.1)
N1 12 (23.5) 3 (25) 9 (23.1)
N2 15 (29.4) 3 (25) 12 (30.8)
Nx (fewer than 12 harvested nodes) 10 (19.6) 2 (16.7) 8 (20.5)
Unknown 11 (21.6) 3 (25) 8 (20.5)
Clinical stage (%) .76
II 3 (5.9) 1 (8.3) 2 (5.1)
III 20 (39.2) 10 (83.3) 10 (25.6)
IV 28 (54.9 1 (8.3) 27 (69.2)
Primary origin (%) .54
Colon 27 (52.9) 6 (50) 21 (53.8)
Rectum 24 (47.1) 6 (50) 18 (46.2)
Synchronicity of liver metastases (%) , .001*
Synchronous 28 (54.9) 1 (8.3) 27 (69.2)
Methacronous 23 (45.1) 11 (91.7) 12 (30.8)
Mean size of liver metastases (cm) 3.01 6 1.8 3.19 6 1.5 3.07 6 1.9 .87
More than three hepatic lesions (%) 13 (28.9) 1 (8.3) 12 (30.8) .13
Incomplete resection rate (R1; %) 7 (13.7) 2 (16.7) 5 (12.8) .63
Recurrence proportion after
metastasectomy during follow-up
36 (70.6) 10 (83.3) 26 (66.7) .23
*Statistically significant at P , .05.
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performed in eight cases, and the remaining pa-
tients received systemic chemotherapy. Only five
patients could not receive further therapy due to a
poor performance status score.
Figure 2 shows the probability of DFS according to
treatment received. There were no significant dif-
ferences between surgery-only patients and those
who also received systemic therapy (P = .20).
DISCUSSION
The survival benefit from complete hepatic resec-
tion in patients with limited liver metastases from
CRC is well established.9 Nevertheless, the role of
systemic therapy followingmetastasectomy is cur-
rently under debate.10 Two randomized trials have
shown a significant improvement in progression-
free survival (as the primary end point) in patients
receiving chemotherapy versus observation alone
after hepatic resection. Both these trials were
prematurely closed because of slow accrual; how-
ever, the pooled analysis of these trials showed a
nonsignificant trend toward better OS in patients
receiving adjuvant therapy.4,11 On the other hand,
the EORTC (European Organization for Research
and Treatment of Cancer) 40983 trial did not find
any survival benefit after a median follow-up of
8.5 years in patients treated with perioperative
FOLFOX4 comparedwith patients who underwent
surgery alone, even when the 3-year progression-
free survival increased to an absolute risk of 9.2%
in patients who underwent resection.12
In our retrospective study, we demonstrate that
patients receiving systemic therapy had a better
3-year OS than patients who underwent surgery
alone, regardless of the regimen (neoadjuvant,
perioperative, or adjuvant). Furthermore, our re-
sults are from a real-world setting, showing the
clinical efficacy and good outcomes of this treat-
ment modality (ie, the use of systemic therapy
and resection of liver metastases).
The discrepancies between our data and those
from previous clinical trials could be the result
of different regimens used or of different patient
populations. For example, among patients in the
EORTC 40983 trial, 66% had metachronous dis-
ease, whereas the majority of our patients had
synchronousmetastases. In fact, previous studies
have demonstrated that patients with metachro-
nous liver metastases have a poor OS compared
with patients diagnosed with synchronous dis-
ease.13 Because the vast minority of our patients
with metachronous metastases did not receive
systemic treatment, we cannot conclude that there
wasany real therapeuticbenefit of this approach in
this particular subgroup. Nevertheless, other au-
thors have also shown the absence of DFS and OS
benefit in patients treated with adjuvant FOLFOX
after resection of metachronous liver metastases,13
whereas other authors have shown some efficacy
of medical treatment in this subgroup.14
In our study,we found that the relapse rate (70.6%)
was similar to that reported previously in the lit-
erature.3 It makes it reasonable to administer
systemic treatment to these patients to increaseDFS
andeventually to improveOS.However,wedidnot
find any significant differences among patients
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Fig 1 –
Probability of overall
survival (Kaplan-Meier
method) according to
treatment received (hazard
ratio, 0.37; 95% CI, 0.15 to
0.91; log-rank test,
P = .025).
Fig 2 –
Probability of disease-free
survival (Kaplan-Meier
method) according to
treatment received (hazard
ratio, 0.62; 95% CI, 0.3 to
1.3; log-rank test, P = .20).
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according to treatment received in terms of DFS.
This could be attributed to a type II error, because
our sample size was small and the study’s design
was retrospective. Despite these caveats and the
low statistical power, we did find a significant
difference in OS among patients treated with sur-
gery aloneversus thosewho receivedany systemic
treatment modality before and/or after metasta-
sectomy. These results are in agreement with a
recentmeta-analysis that showed a 23% improve-
ment in OS among patients treated with liver
metastasectomy plus chemotherapy, regardless
of the timing of administration.6
Our study does have some limitations. The small
sample size and the retrospective design of this
study could overestimate the magnitude of the
reported outcomes.15 Similarly, selection bias
was likely to occur as a result of the nonrandomized
selection of the included patients and the retro-
spective nature of our data.
There are scarce data related to this procedure
in Latin American countries. Indeed, the major-
ity of trials have been conducted in developed
regions with different ethnic populations. Our
results contribute to current evidence support-
ing the use of systemic therapy as part of the
management of patients with resectable liver
metastases, although a prospective clinical trial
is needed to better clarify this approach.
In summary, our findings support the indication of
systemic therapy before and/or after resection of
CRC liver metastases because of its significant OS
benefit in a real-world population.
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